Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience

The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some...

Descripción completa

Detalles Bibliográficos
Autores principales: Nan, Feifei, Fu, Xiaorui, Chen, Xinfeng, Li, Ling, Li, Xin, Wu, Jingjing, Feng, Xiaoyan, Wu, Xiaolong, Yan, Jiaqin, Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399606/
https://www.ncbi.nlm.nih.gov/pubmed/36032118
http://dx.doi.org/10.3389/fimmu.2022.929221
_version_ 1784772562192957440
author Nan, Feifei
Fu, Xiaorui
Chen, Xinfeng
Li, Ling
Li, Xin
Wu, Jingjing
Feng, Xiaoyan
Wu, Xiaolong
Yan, Jiaqin
Zhang, Mingzhi
author_facet Nan, Feifei
Fu, Xiaorui
Chen, Xinfeng
Li, Ling
Li, Xin
Wu, Jingjing
Feng, Xiaoyan
Wu, Xiaolong
Yan, Jiaqin
Zhang, Mingzhi
author_sort Nan, Feifei
collection PubMed
description The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some patients are resistant to this treatment, leaving them with limited options. Therefore, strategies to overcome resistance to CAR-T cell therapy are needed. We retrospectively studied three R/R diffuse large B-cell lymphoma patients who were resistant to CAR-T cell therapy and whose disease was controlled after receiving pembrolizumab, 21D4 CAR-T cells, or ibrutinib and venetoclax. Some promising prevention and treatment strategies to overcome treatment resistance are also discussed.
format Online
Article
Text
id pubmed-9399606
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93996062022-08-25 Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience Nan, Feifei Fu, Xiaorui Chen, Xinfeng Li, Ling Li, Xin Wu, Jingjing Feng, Xiaoyan Wu, Xiaolong Yan, Jiaqin Zhang, Mingzhi Front Immunol Immunology The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some patients are resistant to this treatment, leaving them with limited options. Therefore, strategies to overcome resistance to CAR-T cell therapy are needed. We retrospectively studied three R/R diffuse large B-cell lymphoma patients who were resistant to CAR-T cell therapy and whose disease was controlled after receiving pembrolizumab, 21D4 CAR-T cells, or ibrutinib and venetoclax. Some promising prevention and treatment strategies to overcome treatment resistance are also discussed. Frontiers Media S.A. 2022-08-10 /pmc/articles/PMC9399606/ /pubmed/36032118 http://dx.doi.org/10.3389/fimmu.2022.929221 Text en Copyright © 2022 Nan, Fu, Chen, Li, Li, Wu, Feng, Wu, Yan and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Nan, Feifei
Fu, Xiaorui
Chen, Xinfeng
Li, Ling
Li, Xin
Wu, Jingjing
Feng, Xiaoyan
Wu, Xiaolong
Yan, Jiaqin
Zhang, Mingzhi
Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
title Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
title_full Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
title_fullStr Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
title_full_unstemmed Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
title_short Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
title_sort strategies to overcome car-t cell resistance in clinical work: a single-institute experience
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399606/
https://www.ncbi.nlm.nih.gov/pubmed/36032118
http://dx.doi.org/10.3389/fimmu.2022.929221
work_keys_str_mv AT nanfeifei strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience
AT fuxiaorui strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience
AT chenxinfeng strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience
AT liling strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience
AT lixin strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience
AT wujingjing strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience
AT fengxiaoyan strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience
AT wuxiaolong strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience
AT yanjiaqin strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience
AT zhangmingzhi strategiestoovercomecartcellresistanceinclinicalworkasingleinstituteexperience

Ejemplares similares